Laurion Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Laurion Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-337,109	Closed	-$15.1M	–	836
2021 Q2	$15.1M	Buy	337,109 +189,704	+129%	+$6.26M	0.08%	172
2021 Q1	$3.82M	Buy	147,405 +17,247	+13%	+$436K	0.02%	361
2020 Q4	$2.62M	Buy	+130,158	New	+$2.8M	0.02%	319
2019 Q2	–	Sell	-85,641	Closed	-$1.08M	–	1125
2019 Q1	$1.08M	Buy	85,641 +68,541	+401%	+$605K	0.01%	497
2018 Q4	$115K	Sell	17,100 -48,342	-74%	-$383K	﹤0.01%	1012
2018 Q3	$673K	Buy	+65,442	New	+$563K	0.01%	770

Other funds holding PTGX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Laurion Capital Management's PTGX Position: Q3 2021 in Review

Laurion Capital Management sold out of Protagonist Therapeutics (PTGX) in Q3 2021, closing a stake of 337,109 shares — an estimated $15.1M sold.

Laurion Capital Management first reported a position in PTGX in Q3 2018 and held it in 6 quarters. The position peaked at $15.1M in Q2 2021. 132 funds tracked by Wall St. Rank hold PTGX as of Q3 2021.

Laurion Capital Management reported no remaining Protagonist Therapeutics position as of Q3 2021 after selling out during the quarter.
Laurion Capital Management sold 337,109 Protagonist Therapeutics shares in Q3 2021, an estimated $15.1M.
Laurion Capital Management first reported a position in Protagonist Therapeutics in Q3 2018 and held it in 6 quarters.
Laurion Capital Management's Protagonist Therapeutics position peaked at $15.1M in Q2 2021.
132 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2021.

Based on Laurion Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.